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A new series of arylmethylene hydrazine derivatives bearing 1,3‑dimethylbarbituric moiety 7a–o 
were designed, synthesized, and evaluated for their in vitro urease inhibitory activity. All the 
title compounds displayed high anti‑urease activity, with  IC50 values in the range of 0.61 ± 0.06–
4.56 ± 0.18 µM as compared to the two standard inhibitors hydroxyurea  (IC50 = 100 ± 0.15 μM) 
and thiourea  (IC50 = 23 ± 1.7 μM). Among the synthesized compounds, compound 7h with 2‑nitro 
benzylidene group was found to be the most potent compound. Kinetic study of this compound 
revealed that it is a mix‑mode inhibitor against urease. Evaluation of the interaction modes of the 
synthesized compounds in urease active site by molecular modeling revealed that that compounds 
with higher urease inhibitor activity (7h, 7m, 7c, 7l, 7i, and 7o, with  IC50 of 0.61, 0.86, 1.2, 1.34, 1.33, 
1.94 μM, respectively) could interact with higher number of residues, specially Arg609, Cys592 (as 
part of urease active site flap) and showed higher computed free energy, while compounds with lower 
urease activity (7f, 7n, 7g, and 7a with  IC50 of 3.56, 4.56, 3.62 and 4.43 μM, respectively) and could 
not provide the proper interaction with Arg609, and Cys592 as the key interacting residues along 
with lower free binding energy. MD investigation revealed compound 7h interacted with Arg609 and 
Cys592 which are of the key residues at the root part of mobile flap covering the active site. Interacting 
with the mentioned residue for a significant amount of time, affects the flexibility of the mobile flap 
covering the active site and causes inhibition of the ureolytic activity. Furthermore, in silico physico‑
chemical study of compounds 7a–o predicted that all these compounds are drug‑likeness with 
considerable orally availability.
Helicobacter pylori (H. pylori) is one of the bacteria that has caused many problems for humans by lowering their 
quality of  life1. This bacteria in addition to causing a variety of gastrointestinal disorders, can even cause gastric 
 cancer2. A most common treatment for inhibition of colonization of H. pylori is use of a triple therapy containing 
a proton pump inhibitor and two antibiotic  agents3. The use of this treatment and similar treatments, in addition 
to causing side effects in other organs of the body, has led to H. pylori antibiotic  resistance4. Therefore, the use 
of methods that specifically attack to bacteria is very valuable in the treatment of this  disease5. One of the most 
popular of these methods is the use of H. pylori urease  inhibitors6. H. pylori, like many other microorganisms, 
uses urea for growth, thus, the enzyme that breaks down urea, urease, plays an important role in its  survival7. 
Several urease inhibitors with various structures have been introduced that can be useful for treatment of H. 
pylori  infection8–10.
Recently, barbituric acid and its derivatives such as 1,3-dimethylbarbituric and thiobarbituric have received 
increasing attention in the discovery of new urease  inhibitors11–13. Several compounds possessing barbituric 
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acid derivatives such as compounds A display high inhibitory activity against urease (Fig. 1)14. As can be seen 
in Fig. 1, the later compounds have a 5-aminomethylene-1,3-dimethylbarbituric moiety. On the other hand, 
Saeed et al. reported the synthesis of a series of arylmethylene hydrazine derivatives containing carbothioamide 
B as novel urease  inhibitors15. Their biological data demonstrated that the most potent compound among the 
compounds B showing up to 36.2-fold higher inhibitory potency than standard inhibitor thiourea (Fig. 1). By 
considering the potent urease inhibitors A and B, in continuing our efforts to synthesize new urease inhibitors 
using simple chemical reactions, here, a new series of urease inhibitors 7a–o was designed by combination of 
5-aminomethylene-1,3-dimethylbarbituric moiety and arylmethylene hydrazine derivatives (Fig. 1)16–20. Com-
pounds 7a–o were synthesized by a simple three-step procedure. All these compounds were evaluated for their 
in vitro urease inhibitory activities. Furthermore, molecular modeling and molecular dynamic studies of com-
pounds 7a–o were also performed.
Results and discussion
Chemistry. Arylmethylene hydrazine-1,3-dimethylbarbituric derivatives 7a–o were synthesized by described 
method in Fig. 2. According to this method, reaction of 1,3-dimethylbarbituric acid 1 and trimethoxymethane 
2 in ethanol under reflux condition afforded 5-(methoxymethylene)-1,3-dimethylbarbituric acid 3. The latter 
compound was reacted with hydrazine 4 in ethanol under reflux for produce 5-(hydrazineylmethylene)-1,3-di-
methylbarbituric acid 5. In the final step, compound 5 and aromatic aldehydes 6a–o in the presence of catalytic 












































































Figure 2.  Synthesis of arylmethylene hydrazine-1,3-dimethylbarbituric derivatives 7a–o.
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Urease inhibition. The effect of arylidenehydrazineyl-1,3-dimethylbarbituric derivatives 7a–o on urease 
was determined using Jack bean (JB) urease in accordance to the reported  protocols18–20. The obtained  IC50 val-
ues of title compounds against urease were presented in Table 1, in comparison with hydroxyurea and thiourea 
as reference inhibitors.
Generally, all newly synthesized compounds 7a–o, with  IC50 values in the range of 0.61 ± 0.06–4.56 ± 0.18 μM, 
had significant inhibitory effect against urease. All these compounds were more potent than that of hydroxyurea 
 (IC50 = 100 ± 0.15 μM) and thiourea  (IC50 = 23 ± 1.7 μM). The 2-nitrophenyl derivative 7h and thiophen-2-yl 
derivative 7m with  IC50 values of 0.61 ± 0.06 and 0.86 ± 0.08 μM were found to be the most active compounds. 
In particular, compound 7h was 37.7 times more potent than strong urease inhibitor thiourea.
Un-substituted phenyl derivative 7a, and 2,3-dichlorophenyl derivative 7j, were weaker than other phenyl 
derivatives against urease. Among the phenyl derivatives, the most potent compound was 2-nitro derivative 7h. 
The activity of this compound was 7.2-fold superior to that of parent phenyl derivative 7a. Movement of nitro 
substituent of 2-position into 4-position, as in compound 7i, and or replacement of 2-nitro group with 2-hydroxy 
substituent, as in compound 7b, decreased inhibitory activity to about two and fivefold, respectively. Moreover, 
introduction of 2,3-dichloro (compound 7j), 2-chloro-5-nitrophenyl (compound 7k), 3-bromo (compound 7g), 
4-chloro (compound 7f), 3-phenoxy (compound 7e), and 3,4,5-trimethoxyphenyl (compound 7d) substituents 
instead of 2-nitro substituent dramatically decreased anti-urease activity while presence of 2,4-hydroxy (com-
pound 7c) and 2-nitro-5-chloro (compound 7l) substituents on phenyl ring reduced inhibitory activity with less 
intensity in comparison to 2-nitro substituent.
The second most potent compound among the synthesized compound was thiophen-2-yl derivative 7m. 
As can be seen in Table 1, introduction of 5-chloro substituent on thiophen ring, as in compound 7n, led to a 
significant decrease in inhibitory activity. Furthermore, naphthalen-1-yl derivative 7o was one of the strongest 
compounds among the synthesized compounds.
Urease kinetic study. To evaluate the mechanism inhibition of new arylmethylene hydrazine-1,3-dimeth-
ylbarbituric derivatives, kinetics study was performed on the most potent urease inhibitor 7h (Fig. 3). The inhi-
bition mode and  Ki value were determined by Lineweaver–Burk plots and secondary re-plotting of the men-
tioned plots, respectively. As exhibited in Fig. 3a, with increasing concentrations of compound 7h,  Vmax and  Km 
increased. Therefore, this compound was a mixed-type inhibitor for urease (Fig. 3b,  Ki = 0.82 µM).
Docking study. Docking study was applied to distinguish interactions between the synthesized compounds 
and urease active site. The reliability of the applied docking protocol was assessed according to our previous 
Table 1.  The  IC50 values (μM) of compounds 7a–o against urease. a Values are the mean ± standard error of the 









Compound R IC50 (μM)a
7a Phenyl 4.43 ± 0.21
7b 2-Hydroxyphenyl 3.09 ± 0.13
7c 2,4-Hydroxyphenyl 1.2 ± 0.05
7d 3,4,5-Trimethoxyphenyl 2.53 ± 0.11
7e 3-Phenoxyphenyl 2.85 ± 0.23
7f 4-Chlorophenyl 3.56 ± 0.16
7g 3-Boromophenyl 3.62 ± 0.19
7h 2-Nitrophenyl 0.61 ± 0.06
7i 4-Nitrophenyl 1.31 ± 0.09
7j 2,3-Dichlorophenyl 4.52 ± 0.31
7k 2-Chloro-5-nitrophenyl 3.94 ± 0.25
7l 2-Nitro-5-chlorophenyl 1.34 ± 0.12
7m Thiophen-2-yl 0.86 ± 0.08
7n 5-Chlorothiophen-2-yl 4.56 ± 0.18
7o Naphthalen-1-yl 1.94 ± 0.22
Hydroxyurea – 100 ± 0.15
Thiourea – 23 ± 1.7
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study by re-docking of acetohydroxamic acid (AHA) into the active site of the JB  urease20. This protocol was then 
similarly applied to all the synthesized compounds 7a–o.
The interaction mode of the top IFD scoring of all the synthesized compounds (7a–o) showed they success-
fully occupied in the bi-nickel active site cavity.
Figure 4a shows the top IFD pose of the compounds over JB urease. The result depicts superimposing of 
barbituric acid ring of all the compounds pointed toward the bi-nickel center atoms through the carbonyl group 
at  C2 position of the barbiturate ring (Fig. 4b). The orientation of the mentioned carbonyl group is the same as 
the carbonyl oxygen in the AHA and thiourea as reference inhibitors. Furthermore, the arylmethylene hydra-
zine moieties oriented to the entering site of the active site and adapted by flexible conformation in the large 
hydrophobic opening of the active site flap pocket (Fig. 4a). The mentioned extended moiety in designing of the 
synthesized compounds has the superior inhibitory effect in comparison to the standard inhibitor (thiourea) 
through higher stabilization effect by implementing of various non-bonding interactions.
In case of the most active compound 7h (Fig. 5), the carboxyl groups in  C2 and  C4 position of barbituric acid 
ring created H-bond with His492 and Arg609, the hydrazone group formed H-bond interaction through Cys592 
(SH) and the ortho nitro benzylidene group was able to form salt-bridge interaction toward Arg639 (Fig. 5a). As 
a result, compound 7h well occupied the active pocket of urease and tightly anchoring the helix-turn-helix motif 
through interacting with Cys592 and Arg609 over the active-site cavity (depicted in green cartoon) (Fig. 5b), 
which could reduce the flexibility of flap residue (590–609) and results in the inhibition of urease activity.
In order to reveal the effect of different aromatic ring instead of phenyl ring, the docked pose complex and 
the gibbs free binding energy (ΔG) of the compounds 7a, 7m and 7o were compare to each other.
Figure 6a shows barbituric acid ring of compound 7a tightly coordinated along the metal bi-nickel center 
and further stabilized by H-bond interaction with His492. At the middle part of the molecule, the hydrazone 
group formed H-bond interaction through Cys592 (SH). In addition, the benzylidene group at the tail part of 
Figure 3.  Kinetic analysis of urease inhibition by compound 7h. (a) The Lineweaver–Burk plot in the absence 
and presence of different concentrations of compound 7h; (b) The secondary plot between 1/Vmax and various 
concentrations of compound 7h.
Figure 4.  Representation of the compounds docking poses over the active site (a) close-up illustration of 
barbiturate ring relative to the bi-nuclear center (b), the active site flap colored in green color. The molecular 
graphic in this figure was generated using VMD 1.9.3.
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:10607  | https://doi.org/10.1038/s41598-021-90104-x
www.nature.com/scientificreports/
the compound formed hydrophobic interaction with hydrophobic pocket formed by Cys592, Met588, Val 591 
and Leu589.
Like compound 7a, compounds 7m and 7o, which have different aromatic moieties (thiophenyl and naphthyl, 
respectively), formed similar H-bond interactions through their barbituric acid ring and hydrazone group with 
His492 and Cys592, respectively. The gibbs free binding energy indicates higher value (ΔG) of − 46.47 and − 44.27, 
respectively as compared to compound 7a with ΔG value of − 39.52 kcal  mol−1 (Table 2), which is in accordance 
with the experimental urease activity results (0.86, 1.94 and 4.43 μM, respectively, Table 1). In the case of com-
pound 7m, the sulfur atom increased hydrophobic interaction by interacting with the mentioned hydrophobic 
pocket through sulfur atom of Met388, while in the case of compound 7o, the naphthyl ring rotated as a result 
of bigger size and interacted with the imidazole ring of His594 by π–π stacking interaction (Fig. 6b,c).
The result shows that the bioisoester substitution of phenyl group provides additional interactions for the 
compounds 7m and 7o to bind to the hydrophobic part of urease active site pocket.
This study confirms our previous investigation which outstands the key role of Cys592 and Arg609 in flex-
ibility of mobile flap covering the active site entrance which consequently affect the inhibition activity of urease 
 enzyme21.
Table 2 shows the interaction part of the molecule, the involving residues and the calculated gibbs free binding 
energies of the compound with higher and lower urease inhibition activity over JB urease active site. It indicates 
that compounds with higher urease inhibitor activity (7h, 7m, 7c, 7l, 7i, and 7o, with  IC50 of 0.61, 0.86, 1.2, 1.34, 
1.33, 1.94 μM, respectively) could interact with higher number of residues, specially Arg609, Cys592 (as part of 
urease active site flap), while compounds with lower urease activity (7f, 7n, 7g, and 7a with  IC50 of 3.56, 4.56, 
3.62 and 4.43 μM, respectively) have insufficient interaction and could not provide the proper interaction with 
Figure 5.  Close up representation of the best energy value of the most active compound 7h complexed with JB 
urease (a), 90-degree anti-clockwise rotation view (b). The molecular graphic in this figure was generated using 
VMD 1.9.3.
Figure 6.  3D representation of ligand-residue interactions of compound 7a (a), compound 7m (b), compound 
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Arg609, and Cys592 as the key interacting residues. Furthermore, this finding additionally supported by compar-
ing the gibbs free binding energy of the mentioned compounds which are in accordance with the experimental 
urease inhibition activity.
Conformational analyses of the synthesized compounds over the urease active site. As the 
synthesized compounds hold benzylidene hydrazone moiety, they may adopt in four possible geometrical con-
figurations including; the anti-periplanar (ap) and syn-planar rotameric (sp) forms for each Z and E isomers as 
shown in Fig. 7a. The superimposed structures of IFD compounds over the active site of JB urease have been 
shown in Fig. 7b. It represents that n-π conjugation result in a planar form of C=N–NH moiety. Considering 
Fig. 7a isomer E with anti-periplanar rotamer was the only configuration while no docked-structures got the Z 
configuration around C=N bond. This result is in accordance well with a previously reported study where there 
is no Z configuration around C=N of benzylidene hydrazone moiety due to the steric  hindrance22–24. Therefore, 
according to the result it reveals that the E-ap form is the preferred geometrical isomer by the benzylidene hydra-
zone structure of barbituric acid derivatives.
Molecular dynamic (MD) investigation. MD study has been investigated in order to reveal the effect of 
the most potent compound (compound 7h) on the urease structure and the active site environment in compari-
son to thiourea as the urease standard inhibitor.
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Figure 8 shows the RMSD of the protein’s backbone over 100 ns MD simulation time. The RMSD simulation 
showed urease complexed with thiourea maintained an overall stability after 35 ns of MD simulation time with 
higher RMSD stabilizing at an average of 3.80 Å (Fig. 8, green line), while urease bound-state with compound 
7h displayed longer equilibration time (after 15 ns of MD simulation) with obviously lower RMSD (2.4 Å) 
(Fig. 8, red line). In addition, the backbone RMSD of compound 7h equilibrated after about 40 ns and stabilized 
through the rest of the simulation time with a low RMSD fluctuation around 1.1 Å. Based on the RMSD result 
it is revealed that the urease-compound 7h complex obtain an equilibrium structure over the simulation time 
which has enough stability to investigate the structural specificity of the ligand–protein complex.
RMSF define as the fluctuation of the protein’s residues from its average position throughout the simulation, 
which represents the flexibility of protein structure. In this manner, helixes and sheets with organized structure 
Figure 7.  Four possible configurations of benzylidene hydrazone moiety of the synthesized compounds (a). 
Superimposition of the docked structures in the active site of urease (b). The 2D structure representation was 
drawn by ChemAxon Marvin 15.10.12.030.
Figure 8.  RMSD representation of the compound 7h (in yellow) and urease backbone in complex with thiourea 
(in green) and in complex with compound 7h (in red) for over 100 ns MD simulation time. The plot in was 
generated using Microsoft Excel (https:// www. office. com/).
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depict lower RMSF value while loops with loosely organized structure have high RMSF value. Comparing RMSF 
values of urease-compound 7h complex shows that it has obviously lower value through the whole part of the 
urease structure and specially the residues 590–606 showed significantly decreased RMSF value in the urease 
bound-state with compound 7h than urease-thiourea complex (Fig. 9a). The mentioned conserved residues with 
helix-turn-helix secondary structure belong to the α-subunit part of the enzyme known as mobile flap region 
covering the urease active  site25.
Figure 9b shows that compound 7h well occupied the active pockets of urease and tightly anchoring the 
helix-turn-helix motif over the active-site cavity (vertical green line), which considerably reduce the flexibility 
of the mobile flap residue (590–609) by interacting with key amino acid residues and results in the inhibition 
of urease activity. The mentioned interactions could not be observed for the urease-thiourea complex which 
proposed the role of rigidity of the mobile flap in higher urease inhibition activity of the synthesized compounds.
Figure 10 represents different residues, types of interactions, and ligands functional group involvement dur-
ing the whole MD simulation time.
Based on result, compound 7h interacted with Arg439, Ala440, Lys490, His519, His545, Gly550, Asp633 and 
Ala636 for approximate the first 10 ns of the MD simulation (Fig. 10a, red dash boxes). Otherwise, after about 
14.32 ns until to the end of simulation the metal-coordinated residue interactions disappeared and substituted 
with residues; Thr522, Gly548, Leu589, Cys592, His593, Arg609, Arg611, Ile610, and Met637 (Fig. 10a, blue 
dash boxes).
So, because of the shifting orientation of compound 7h as a result of different interacting residues, the MD 
simulation time divided in two sections; 0 ns to 14.32 ns and 14.32 ns to 100 ns. Based on the cluster analysis of 
compound 7h, the percent of population in cluster 1 was 86.37% in the first section and 95% in the second sec-
tion in which the representative frame from cluster 1 of the section 1 (Fig. 10b, up) and the section 2 (Fig. 10b, 
down) were selected for investigating the 3D complex interaction.
As it is obvious in Fig. 10b (up), at the first stage of MD compound 7h tightly coordinated toward the active 
site bi-nickel center through its barbituric acid. In addition, the ortho nitro benzylidene moiety provided ion-
bridge and π-cation interactions through Arg439. Otherwise, after about 14 ns the barbituric acid ring shifted 
from the bi-nickel center toward the active site flap and provided interactions with Cys592, His593 at one side 
and Arg609 and Arg611 at the other side of the active site flap while the ortho nitro benzylidene moiety still 
stabilized in its initial position faced to Arg439 through the electrostatic interaction (Fig. 10b, down) (the types 
of residue interactions during the MD simulation represents in different color by Fig. 10c). So, it can propose 
Figure 9.  RMSF of the urease backbone in complexed with thiourea (in green) and compound 7h (in red) (a), 
ligand binding location for over 100 ns MD simulation time; (b) α-helical and ß-strand regions are highlighted 
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Figure 10.  The timeline representation of the interactions shows the residues interact with compound 7h in 
each trajectory frame (more than one specific contact with the ligand is represented by a darker shade of orange) 
(a). The 3D representation of urease in bound-state with compound 7h in two different orientations related to 
0–14.32 ns and 14.32 to the rest of simulation time (active site flap are depicted in green cartoon mode) (b). The 
simulation interactions diagram panel. The stacked bar charts are normalized over the course of the trajectory: 
some protein residues may make multiple contacts with the ligand (c). 2D representation of ligand-residue 
interactions that occur at least 30% of simulation time of urease bound-state of thiurea and compound 7h (d). 
The molecular graphic in this figure was generated using VMD 1.9.3.
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that compound 7h provides the stabilized interaction to Arg439 at the opening part of the active site through 
its polar nitro substitution. This finding is in accordance with our experimental results as the molecular level 
explanation on the higher urease activity of compound 7h and the compounds with polar substituent at the 
phenyl ring. Also, again the E-ap conformer, as the preferred geometrical isomer by the benzylidene hydrazone, 
recognized for both stages of MD simulation time.
Furthermore, Fig. 10d shows the detailed 2D-ligand atom interactions that occurred more than 30.0% of 
the simulation time during the equilibrated phase over urease complexed with thiourea and compound 7h. The 
interaction analysis suggests compound 7h stabilized by the ortho nitro group with Arg439 at the entrance of 
active site through salt-bridge interaction for about 43% of simulation time. Also, it formed water-mediated 
H-bond interaction with Arg609 and Arg611 at on side of the active site flap through the C4 carbonyl group of 
barbituric acid ring for 45% and 55% of simulation time, respectively. In addition, Cys592 on the other side of 
the active site flap provided the non-bonding interaction mostly through hydrophobic interaction for about 45% 
of MD simulation time (Fig. 10c, Cys592 bar chart).
It is noteworthy that Arg609 and Cys592 are of the key residues at the root part of mobile flap covering the 
active site. Interacting with the mentioned residue for a significant amount of time, affects the flexibility of the 
mobile flap covering the active site and causes inhibition of the ureolytic  activity20.
Comparing the results of compound 7h interaction with thiourea indicates thiourea did not show any inter-
action with these key residues at the active site flap region which can proposed the reason of higher urease 
inhibition activity of compound 7h rather than thiourea.
In silico prediction of pharmacokinetic properties. The main physico-chemical properties of the syn-
thesized compounds, which represent drug-likeness, partition coefficient, solubility, cell permeation, were cal-
culated. Aiming to discuss the reliability of predictions in a consensus way, the parameters calculated with two 
different software. The partition coefficient (Log P) predicted by Qikpro module of schrodinger and swissADME 
web server while solubility (Log S), cell permeation and the predicted % human absorption (oral; %HOA and 
intestinal; %HIA) were measured based on Qikpro and pkCSM web server.
“Lipinski rule of five” was used to assess the drug-likeness of the synthesized compounds which includes 
calculating of the molecular weights, number of hydrogen bond donor, number of hydrogen bond acceptor and 
the predicted octanol/water partition co-efficient. According to Table 3, the number of violations of Lipinski’s 
rule of five (ROF violations) for all the synthesized compounds was zero (0) and therefore all compounds (7a–o) 
meet the drug-likeness  criteria26.
Also, the bioavailability of a compound mainly depends on the absorption and metabolism process. The oral 
and gastrointestinal absorption procedures in turn relay on the solubility and permeability of the a  compound27. 
The computed physico-chemical parameters used to assess absorption of the newly synthesized compounds 
7a–o and hydroxyurea including; the predicted aqueous solubility (Log S), the predicted apparent Caco-2 cell 
permeability as a model for the gut-blood barrier (non-active transport) (PCaco-2 and LogCaco-2), the predicted 
% human absorption (oral; %HOA and intestinal; %HIA) which were measured based on two different meth-
ods Qikpro and pkCSM web server and presented in Table 4. Comparing the experimental solubility value of 
Table 3.  The calculated physico-chemical property of the synthesized compounds 7a–o for predicting 
drug-likeness based on Lipinski-rule of five. a Molecular weights (acceptable value ≤ 500). b Number of average 
Hydrogen Bond Donor (acceptable value ≤ 5). c Number of average Hydrogen Bond Acceptor (acceptable 
value ≤ 10). d Predicted octanol/water partition co-efficient (acceptable value ≤ 5). e Number of violations of 
Lipinski’s rule of five (maximum 4).
Compound MWa HBDb HBAc
LogP o/wd
ROF  violationsfQikpro SwissADME (iLog P)
7a 286.290 5 1 2.297 2.56 0
7b 302.289 2 5 1.373 1.72 0
7c 318.288 3 6 1.018 1.37 0
7d 376.368 1 7 2.354 3.02 0
7e 378.387 1 5 3.655 2.86 0
7f 320.735 1 4 2.627 2.55 0
7g 365.186 1 4 2.694 2.73 0
7h 331.287 1 6 1.412 1.6 0
7i 331.287 1 6 1.357 2.07 0
7j 355.180 1 4 2.993 2.49 0
7k 365.732 1 6 1.802 1.71 0
7l 365.732 1 6 1.916 1.90 0
7m 292.312 1 4 2.010 1.76 0
7n 326.757 1 4 2.522 2.4 0
7o 336.349 1 4 3.055 2.54 0
Hydroxyurea 76.06 3 2 − 0.2 − 0.16 0
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hydroxyurea which considered as 100 mg/ml (experimental Log S of 1.2 mol/L) with the calculated Log S value of 
1.1 (Table 4, Qikpro method) confirm the reliability of calculated data. Based on Jorgensen’s rule of three, orally 
availability is determined by calculating descriptor expressed as: log Swat >  − 5.7, PCaco-2 > 22 nm/s, and Primary 
Metabolites <  728. According to Table 4, all the titled compounds follow of Jorgensen’s rule of three. Moreover, the 
same result has been revealed by implementing the pkCSM web server which proved the resulted outcome. In 
this way, compounds 7a, 7d-g, 7j, and 7m–o exhibited high HOA and the other compounds have moderate HOA.
Conclusion
In summary, a novel series of arylmethylene hydrazine-1,3-dimethylbarbituric derivatives 7a–o have been 
synthesized via simple chemical reactions, and their inhibitory activities against urease were evaluated. In 
the enzymatic assay, all the synthesized compounds 7a–o acted as potent inhibitors against urease  (IC50 val-
ues = 0.61 ± 0.06–4.56 ± 0.18 μM) and were more active than the standard inhibitors hydroxyurea and thiourea 
 (IC50 values = 100 ± 0.15 and 23 ± 1.7 μM, respectively). Furthermore, IFD study of the synthesized compounds 
in the urease active site showed that compounds with higher urease inhibitor activity could interact with higher 
number of residues, specially Arg609, Cys592 and showed higher computed free energy, while compounds with 
lower urease activity could not provide the proper interaction with Arg609, and Cys592 as the key interacting 
residues along with lower free binding energy. MD investigation revealed compound 7h interacted with Arg609 
and Cys592 which are of the key residues at the root part of mobile flap covering the active site. Interacting with 
the mentioned residue for a significant amount of time, affects the flexibility of the mobile flap covering the 
active site and causes inhibition of the ureolytic activity. Moreover, in silico pharmacokinetic study predicted 
that newly synthesized compounds are drug-likeness and can be orally active.
Experimental
Methods. Melting points of arylmethylene hydrazine-1,3-dimethylbarbituric derivatives 7a–o were taken 
on a Kofler hot‐stage apparatus. 1H spectra were recorded on Bruker FT‐500 (500 MHz), and are reported rela-
tive to DMSO-d6 (δ 2.50). 1H NMR coupling constants (J) are reported in Hertz (Hz), and multiplicities are 
indicated as follows: s (singlet), d (doublet), t (triplet), m (multiplet), dd (doublet of doublet), dt (doublet of 
triplet). Proton-decoupled 13C NMR spectra were recorded on Bruker FT‐500 (125 MHz) and reported relative 
to DMSO-d6 (δ 40.0). The infrared (IR) spectra of title compounds were obtained on a Nicolet Magna FT‐IR 
550 spectrophotometer (KBr disks). Elemental analysis of compounds 7a–o was carried out with an Elementar 
Analysensysteme GmbH VarioEL CHN mode. Spectra data of arylmethylene hydrazine-1,3-dimethylbarbituric 
derivatives 7a–o are available in the supplementary information.
Synthesis of 5‑(methoxymethylene)‑1,3‑dimethylbarbituric acid 3. A mixture of 1,3-dimethylb-
arbituric acid 1 (1 mmol) and trimethoxymethane 2 (3 mmol) in ethanol (5 ml) was refluxed for 3 h. Then, 
Table 4.  The calculated physico-chemical properties of the synthesized compounds 7a–o for predicting 
absorption procedure. a Predicted aqueous solubility in mol  dm−3 (− 6.5 to 0.5) (QPlogS > − 5.7). b Predicted 
Caco-2 cell permeability in nm/s. c Percentage human oral absorption (< 25% is poor and > 80% is high). 
d Number of likely metabolic reactions (Primary Metabolites < 7). e Number of violations of Jorgensen’s rule of 
three. Compounds with fewer (preferably no) violations of these rules are more likely to be orally available. 
f Predicted Caco-2 cell permeability of a given compound is given as the log Papp in  10−6 cm/s. g Percent of 
human intestinal absorption, (< 30% is poor and > 30% is high).
No.
Qikpro pkCSM
Log Swata PCaco-2b %  HOAc metabd RO3  Ve Log S LogCaco-2f %HIAg
7a − 3.276 466.539 88.163 0 0 − 2.82 0.491 63.68
7b − 3.452 52.356 67.24 2 0 − 2.73 − 0.051 54.28
7c − 3.558 463.086 63.67 1 0 − 2.42 0.490 51.12
7d − 3.750 466.982 88.503 3 0 − 3.42 0.315 60.12
7e − 5.027 466.528 96.113 0 0 − 4.23 1.11 93.61
7f − 4.043 466.707 90.100 0 0 − 3.52 0.50 67.59
7g − 4.164 466.609 90.490 0 0 − 3.69 0.492 67.71
7h − 3.326 61.598 67.243 1 0 − 3.43 − 0.184 62.36
7i − 3.317 56.002 66.181 1 0 − 3.39 − 0.185 62.43
7j − 4.539 469.380 92.283 0 0 − 4.21 0.874 92.05
7k − 3.941 56.434 68.846 1 0 − 4.01 − 0.203 63.57
7l − 4.088 61.624 70.194 1 0 − 4.01 − 0.20 63.60
7m − 3.210 453.274 86.260 1 0 − 3.10 0.486 70.21
7n − 3.997 453.958 89.268 1 0 − 3.83 0.493 74.30
7o − 4.484 471.159 92.678 0 0 − 3.23 0.448 94.16
Hu 1.1 38.71 40.93 1 0 0.70 0.494 73.12
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this mixture was allowed to stand overnight at room temperature for formation pure 5-(methoxymethylene)-
1,3-dimethylbarbituric acid 3.
Synthesis of 5‑(hydrazineylmethylene)‑1,3‑dimethylbarbituric acid 5. A mixture of 
5-(methoxymethylene)-1,3-dimethylbarbituric acid 3 (1 mmol) and hydrazine 4 (1 mmol) in ethanol (5 ml) was 
refluxed for 1 h. After that, the reaction mixture was allowed to cool at room temperature and poured into water, 
and the pure 5-(hydrazineylmethylene)-1,3-dimethylbarbituric acid 5 were filtered off.
General procedure for the synthesis of Arylmethylene hydrazine‑1,3‑dimethylbarbituric 
derivatives 7a–o. A mixture of the compound 5 (1 mmol), aromatic aldehydes 6a–o (1.5 mmol), PTSA in 
ethanol (10 ml) was was stirred at room temperature for 8 h. The obtained precipitate was filtered off and washed 
with ethanol (2 ml) to give pure compounds 7a–o.
(E)-5-((2-benzylidenehydrazinyl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7a). 
White solid; isolated yield: 96%, mp 172–174 °C; IR (KBr, υ): 3289, 3057, 2929, 1638  cm-1; 1H NMR (301 MHz, 
DMSO-d6) δ 12.71 (s, 1H, NH), 8.78 (s, 1H, CH=N), 8.44 (s, 1H, CH=C), 7.76 (dd, J = 6.6, 2.8 Hz, 2H), 7.54 – 7.48 
(m, 3H), 3.20 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-d6) δ 159.96, 154.44, 151.91, 133.23, 131.74, 129.48, 
128.21, 121.88, 117.10, 90.73, 28.06  (CH3), 27.46  (CH3); Anal Calcd for  C14H14N4O3, C, 58.73, H, 4.93, N, 19.57 
found: C, 58.70, H, 4.98, N, 19.50.
(E)-5-((2-(2-hydroxybenzylidene)hydrazinyl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-
trione (7b). White solid; isolated yield: 83%, mp 173–175 °C; IR (KBr, υ): 3284, 3057, 2939, 1631  cm-1; 1H 
NMR (301 MHz, DMSO-d6) δ 12.62 (d, J = 12.0 Hz, 1H, NH), 10.17 (s, 1H, OH), 8.79 (s, 1H, CH=N), 8.45 (d, 
J = 12.0 Hz, 1H, CH=C), 8.29 (d, J = 7.8 Hz, 1H,  H3), 7.47 (m, 1H,  H4), 6.44 – 6.31 (m, 2H,  H5 &  H6), 3.19 (s, 3H, 
 CH3), 3.18 (s, 3H,  CH3); 13C NMR (76 MHz, DMSO-d6) δ 163.40, 162.41, 159.78, 153.54, 152.64, 151.90, 129.92, 
110.68, 108.72, 102.92, 90.43, 89.77, 28.00  (CH3), 27.39  (CH3); Anal Calcd for  C14H14N4O4, C, 55.63, H, 4.67, N, 
18.53 found: C, 55.65, H, 4.64, N, 18.48.
(E)-5-((2-(2,4-dihydroxybenzylidene)hydrazinyl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-
trione (7c). White solid; isolated yield: 80%, mp 184–186 °C; IR (KBr, υ): 3292, 3048, 2936, 1639  cm-1; 1H NMR 
(301 MHz, DMSO-d6) δ 12.64 (s, 1H, NH), 10.18 (s, 1H, OH), 10.09 (s, 1H, OH), 8.80 (s, 1H, CH=N), 8.46 (s, 
1H, CH=C), 7.48 (d, J = 9.1 Hz, 1H,  H6), 6.42–6.30 (m, 2H), 3.19 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-d6) 
δ 163.41, 162.42, 162.27, 159.79, 153.58, 152.67, 151.95, 129.93, 110.72, 108.75, 102.95, 89.79, 28.02  (CH3), 27.43 
 (CH3); Anal Calcd for  C14H14N4O5, C, 52.83, H, 4.43, N, 17.60 found: C, 52.88, H, 4.40, N, 17.67.
(E)-1,3-dimethyl-5-((2-(3,4,5-trimethoxybenzylidene)hydrazinyl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione (7d). White solid; isolated yield: 94%, mp 197–199 °C; IR (KBr, υ): 3294, 3047, 2931, 
1626  cm-1; 1H NMR (301 MHz, DMSO-d6) δ 12.82 – 12.51 (m, 1H, NH), 8.65 (s, 1H, CH=N), 8.49 (s, 1H), 7.07 
(s, 2H), 3.86 (s, 6H,  2CH3), 3.74 (s, 3H), 3.20 (s, 6H); 13C NMR (76 MHz, DMSO-d6) δ 164.63, 158.97, 155.50, 
150.67, 146.14, 140.03, 126.53, 106.53, 103.88, 94.75, 61.30 (OCH3), 55.46 (OCH3), 27.91  (CH3), 26.53  (CH3); 
Anal Calcd for  C17H20N4O6, C, 54.25, H, 5.36, N, 14.89 found: C, 54.28, H, 5.30, N, 14.88.
(E)-1,3-dimethyl-5-((2-(3-phenoxybenzylidene)hydrazinyl)methylene)pyrimidine-2,4,6(1H,3H,5H)-
trione (7e). White solid; isolated yield: 87%, mp 217–219 °C; IR (KBr, υ): 3281, 3056, 2935, 1639  cm-1; 1H NMR 
(301 MHz, DMSO-d6) δ 12.68 (s, 1H, NH), 8.73 (s, 1H, CH=N), 8.35 (s, 1H, CH=C), 7.52 – 7.41 (m, 4H), 7.32 
(s, 1H,  H6), 7.21 (t, J = 7.4 Hz, 1H), 7.14 (dt, J = 7.2, 2.3 Hz, 1H), 7.08 (d, J = 7.6 Hz, 2H), 3.18 (s, 6H,  2CH3); 
13C NMR (76 MHz, DMSO-d6) δ 157.77, 156.56, 154.46, 153.54, 151.85, 137.88, 135.16, 131.19, 130.66, 126.07, 
124.44, 123.56, 121.67, 119.50, 116.88, 90.88, 27.50  (CH3), 26.08  (CH3); Anal Calcd for  C20H18N4O4, C, 63.48, 
H, 4.79, N, 14.81 found: C, 63.41, H, 4.83, N, 14.86.
(E)-5-((2-(4-chlorobenzylidene)hydrazinyl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-tri-
one (7f). White solid; isolated yield: 92%, mp 179–181 °C; IR (KBr, υ): 3290, 3059, 2928, 1631  cm-1; 1H NMR 
(301 MHz, DMSO-d6) δ 12.73 (d, J = 11.9 Hz, 1H, NH), 8.78 (s, 1H, CH=N), 8.41 (d, J = 11.8 Hz, 1H, CH=C), 
7.76 (d, J = 8.5 Hz, 2H,  H2&H6), 7.57 (d, J = 8.5 Hz, 2H,  H3&H5), 3.21 (s, 3H,  CH3), 3.19 (s, 3H,  CH3); 13C NMR 
(76 MHz, DMSO-d6) δ 159.50, 156.03, 153.92, 149.09, 144.03, 141.19, 137.84, 131.96, 129.32, 98.30, 27.89  (CH3), 
25.25  (CH3); Anal Calcd for  C14H13ClN4O3, C, 52.43, H, 4.09, N, 17.47 found: C, 52.46, H, 4.05, N, 17.52.
(E)-5-((2-(3-bromobenzylidene)hydrazinyl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-tri-
one (7g). White solid; isolated yield: 94%, mp 207–209 °C; IR (KBr, υ): 3293, 3055, 2932, 1637  cm-1; 1H NMR 
(301 MHz, DMSO-d6) δ 12.75 (s, 1H, NH), 8.73 (s, 1H, CH=N), 8.48 (s, 1H, CH=C), 7.94 (s, 1H,  H2), 7.77–7.67 
(m, 2H,  H4&H6), 7.47 (t, J = 7.9 Hz, 1H,  H5), 3.20 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-d6) δ 154.44, 151.91, 
149.42, 143.87, 138.34, 133.23, 131.75, 129.48, 128.21, 122.74, 121.79, 90.73, 27.07  (CH3), 26.78  (CH3); Anal 
Calcd for  C14H13BrN4O3, C, 46.05, H, 3.59, N, 15.34 found: C, 46.09, H, 3.53, N, 15.30.
(E)-1,3-dimethyl-5-((2-(2-nitrobenzylidene)hydrazinyl)methylene)pyrimidine-2,4,6(1H,3H,5H)-trione 
(7h). White solid; isolated yield: 92%, mp 178–180 °C; IR (KBr, υ): 3291, 3048, 2928, 1638  cm-1; 1H NMR 
(301 MHz, DMSO-d6) δ 12.93 (s, 1H, NH), 9.19 (s, 1H, CH=N), 8.43 (d, J = 16.5 Hz, 1H, CH=C), 8.11 (s, 2H), 
7.84 (s, 1H,  H5), 7.74 (s, 1H,  H4), 3.20 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-d6) δ 163.30, 162.20, 153.82, 
151.88, 148.91, 145.29, 140.42, 137.59, 133.56, 131.36, 128.75, 125.09, 90.60, 28.07  (CH3), 27.45  (CH3); Anal 
Calcd for  C14H13N5O6, C, 48.42, H, 3.77, N, 20.17 found: C, 48.40, H, 3.70, N, 20.20.
(E)-1,3-dimethyl-5-((2-(4-nitrobenzylidene)hydrazinyl)methylene)pyrimidine-2,4,6(1H,3H,5H)-
trione (7i). White solid; isolated yield: 86%, mp 171–173 °C; IR (KBr, υ): 3282, 3047, 2934, 1641  cm-1; 1H 
NMR (301 MHz, DMSO-d6) δ 12.83 (s, 1H, NH), 8.89 (s, 1H, CH=N), 8.47 (s, 1H, CH=C), 8.33 (d, J = 8.6 Hz, 
2H,  H3&H5), 8.00 (d, J = 8.7 Hz, 2H,  H3&H5), 3.21 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-d6) δ 162.97, 
156.56, 153.92, 149.09, 143.50, 142.14, 138.90, 130.07, 125.85, 96.11, 28.95  (CH3), 27.36  (CH3); Anal Calcd for 
 C14H13N5O5, C, 50.76, H, 3.96, N, 21.14 found: C, 50.79, H, 3.90, N, 21.20.
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(E)-5-((2-(2,3-dichlorobenzylidene)hydrazinyl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-
trione (7j). White solid; isolated yield: 81%, mp 201–203 °C; IR (KBr, υ): 3296, 3051, 2935, 1635  cm−1; 1H NMR 
(301 MHz, DMSO-d6) δ 12.93 (d, J = 11.7 Hz, 1H, NH), 9.23 (s, 1H, CH=N), 8.38 (d, J = 11.6 Hz, 1H, CH=C), 
7.96 (d, J = 7.9 Hz, 1H,  H4), 7.76 (d, J = 8.0 Hz, 1H,  H6), 7.45 (t, J = 8.0 Hz, 1H,  H5), 3.18 (s, 6H,  2CH3); 13C NMR 
(76 MHz, DMSO-d6) δ 162.76, 160.22, 155.90, 152.72, 146.60, 143.80, 140.40, 135.48, 128.84, 127.02, 124.72, 
124.38, 90.45, 27.78  (CH3), 25.79  (CH3); Anal Calcd for  C14H12Cl2N4O3, C, 47.34, H, 3.41, N, 15.77 found: C, 
47.30, H, 3.45, N, 15.70.
(E)-5-((2-(2-chloro-5-nitrobenzylidene)hydrazinyl)methylene)-1,3-dimethylpyrimidine 
2,4,6(1H,3H,5H)-trione (7k). White solid; isolated yield: 83%, mp 188–190 °C; IR (KBr, υ): 3285, 3052, 2927, 
1633  cm-1; 1H NMR (301 MHz, DMSO-d6) δ 13.02 (s, 1H, NH), 9.25 (s, 1H, CH=N), 8.70 (s, 1H,  H6), 8.50 (s, 1H, 
 H4), 8.29 (d, J = 11.7 Hz, 1H, CH=C), 7.87 (d, J = 8.9 Hz, 1H), 3.20 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-
d6) δ 161.84, 157.69, 154.60, 153.61, 148.63, 144.86, 136.33, 133.08, 131.05, 128.49, 126.00, 125.39, 93.02, 25.80 
 (CH3), 24.88  (CH3). Anal Calcd for  C14H12ClN5O5, C, 45.98, H, 3.31, N, 19.15 found: C, 45.96, H, 3.35, N, 19.13.
(E)-5-((2-(5-chloro-2-nitrobenzylidene)hydrazinyl)methylene)-1,3-dimethylpyrimidine-
2,4,6(1H,3H,5H)-trione (7l). White solid; isolated yield: 88%, mp 191–193 °C; IR (KBr, υ): 3286, 3053, 2934, 
1630  cm-1; 1H NMR (301 MHz, DMSO-d6) δ 13.01 (s, 1H, NH), 9.17 (s, 1H, CH=N), 8.51 (s, 1H,  H6), 8.18–8.13 
(m, 2H), 7.84–7.78 (m, 1H,  H4), 3.21 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-d6) δ 163.82, 161.17, 159.79, 
154.89, 153.82, 147.26, 143.33, 140.07, 134.59, 126.90, 123.77, 122.91, 93.08, 26.30  (CH3), 24.57  (CH3); Anal 
Calcd for  C14H12ClN5O5, C, 45.98, H, 3.31, N, 19.15 found: C, 45.96, H, 3.38, N, 19.21.
(E)-1,3-dimethyl-5-((2-(thiophen-2-ylmethylene)hydrazinyl)methylene)pyrimidine2,4,6(1H,3H,5H)-
trione (7m). White solid; isolated yield: 81%, mp 164–166 °C; IR (KBr, υ): 3288, 3052, 2930, 1635  cm-1; 1H NMR 
(301 MHz, DMSO-d6) δ 12.70 (s, 1H, NH), 8.97 (s, 1H, CH=N), 8.30 (s, 1H, CH=C), 7.81 (d, J = 5.0 Hz, 1H, 
 H5), 7.56–7.52 (m, 1H,  H3), 7.20 (dd, J = 5.0, 3.7 Hz, 1H,  H4), 3.19 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-d6) 
δ 163.30, 162.20, 153.82, 151.88, 148.90, 137.59, 133.56, 131.36, 128.75, 90.60, 28.07  (CH3), 27.45  (CH3); Anal 
Calcd for  C12H12N4O3S, C, 49.31, H, 4.14, N, 19.17 found: C, 49.28, H, 4.17, N, 19.24.
(E)-5-((2-((5-chlorothiophen-2-yl)methylene)hydrazinyl)methylene)-1,3-dimethylpyrimidine-
2,4,6(1H,3H,5H)-trione (7n). White solid; isolated yield: 88%, mp 185–187 °C; IR (KBr, υ): 3293, 3056, 2935, 
1638  cm-1; 1H NMR (301 MHz, DMSO-d6) δ 12.93–12.48 (m, 1H, NH), 8.85 (s, 1H, CH=N), 8.37–8.30 (m, 1H, 
CH=C), 7.47–7.38 (m, 1H,  H4), 7.27–7.19 (m, 1H,  H3), 3.20 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-d6) δ 
162.25, 158.07, 153.90, 151.73, 148.03, 136.80, 133.36, 128.75, 124.66, 90.93, 28.12  (CH3), 27.48  (CH3); Anal 
Calcd for  C12H11ClN4O3S, C, 44.11, H, 3.39, N, 17.15 found: C, 44.17, H, 3.42, N, 17.19.
(E)-1,3-dimethyl-5-((2-(naphthalen-1-ylmethylene)hydrazinyl)methylene)pyrimidine-2,4,6(1H,3H,5H)-
trione (7o). White solid; isolated yield: 90%, mp 213–115 °C; IR (KBr, υ): 3292, 3057, 2933, 1639  cm−1; 1H NMR 
(301 MHz, DMSO-d6) δ 12.82 (s, 1H, NH), 9.53 (s, 1H, CH=N), 8.76 (d, J = 8.4 Hz, 1H,  H2), 8.58 (s, 1H, CH=C), 
8.12–8.02 (m, 3H), 7.73–7.60 (m, 3H), 3.20 (s, 6H,  2CH3); 13C NMR (76 MHz, DMSO-d6) δ 163.43, 155.47, 
147.22, 143.86, 135.72, 133.54, 131.66, 130.81, 129.40, 127.03, 124.78, 123.21, 121.65, 117.64, 97.80, 26.21  (CH3), 
24.66  (CH3); Anal Calcd for  C18H16N4O3, C, 64.28, H, 4.79, N, 16.66 found: C, 64.33, H, 4.72, N, 16.60.
Urease inhibitory activity and kinetic study. All used material and JB urease (EC 3.5.1.5) were pur-
chased from Sigma–Aldrich (USA). Potassium phosphate buffer (PPB) solution with concentration 100 mM 
and pH = 7.4 was prepared in distilled water. Urease inhibition effects of the synthesized compounds 7a–o was 
determined using the modified Berthelot spectrophotometric method by a Synergy H1 Hybrid multi-mode 
microplate reader (BioTek, Winooski, VT, USA) at 625  nm16–20. The enzymatic reactions were performed in PPB 
solution which reach to the 985 μL by adding urea (850 μL) and the synthesized compound (100 μL, 0–10 mg/
mL). Then, urease (15 μL) was added and the concentration of liberated ammonia was measured after 60 min. 
The corresponding concentration of ammonia was determined by addition of the incubated solution (100 μL) to 
the mixture of 500 μL of solution I (5.0 g phenol and 25.0 mg sodium nitroprusside in 500 mL water) and 500 μL 
of solution II (2.5 g sodium hydroxide and 4.2 mL sodium hypochlorite (5% chlorine) in 500 mL water) which 
was incubated at 37 °C for 30 min. The absorbance was obtained by measuring indophenols. The activity of unin-
hibited JB urease was considered as the control activity of 100%. The inhibition assays were conducted according 
to this formula: I (%) = [1 − (T/C)] × 100; where I (%) is the enzyme inhibition, T (test) is the absorbance of the 
analyzed compounds in the presence of urease solution, and C (control) is the absorbance of the solvent in the 
presence of urease solution. Data were expressed as mean ± standard error (SD) and run in triplicate. The  IC50 
values for the all compounds 7a–o were calculated using GraphPad Prism 5 software (GraphPad Software, Inc., 
San Diego, CA). Thiourea and hydroxyurea were used as the standard inhibitors for urease. For the kinetic study 
the urea concentrations were changed from 3.12 to 100 mM and concentrations 0, 0.5, and 1 µM of the most 
potent urease inhibitor was used.
Molecular modeling procedure. In order to find out the interactions mode of designed molecules over 
urease enzyme, Maestro Molecular Modeling platform (version10.5) by Schrödinger, LLC was  performed29. The 
X-ray crystallographic structure of Jack bean urease (JB urease) (in complex with acetohydroxamic acid, AHA) 
was downloaded from the Protein Data Bank (PDB ID; 4h9m) (www. rcsb. org). As urease is reported to be 
functionally active in monomeric state, all the docking studies were performed on single monomer. In addition, 
prosthetic group and co-factors are not directly involved in urease inhibition, so they totally removed before 
docking investigation. Water molecules and co-crystallized ligands were removed from the enzymes crystallo-
graphic structures. The 2D structures of all synthesized compounds were drawn in Marvin 15.10.12.0 program 
(http:// www. chema xon. com) and converted into pdb  file30. The Protein Preparation Wizard and the LigPrep 
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module were used to prepare protein and ligand structure  properly31,32. The missing side chains of the proteins 
were filled using the Prime tool and missing residues were updated.
The accurate side-chain, backbone conformational changes or both during ligand binding at the active site of 
urease enzyme were predicted by IFD method using Glide software (Schrödinger LLC 2018, USA)33. The AHA 
binding site was used to generate the grid for IFD calculation. The maximum 20 poses with receptor and ligand 
van der Waals radii of 0.7 and 0.5, respectively considered. Residues within 5 Å of the AHA at the active site 
were refined followed by side-chain optimization. Structures whose Prime energy is more than 30 kcal/mol are 
eliminated based on extra precious Glide docking.
The ligand binding energies (ΔG bind) were calculated for each synthesized compound using Molecular 
mechanics/generalized born surface area (MM-GBSA) modules (Schrödinger LLC 2018) based on the follow-
ing equation;
where ΔG Bind is the calculated relative free energy which includes both ligand and receptor strain  energy33. 
 EComplex is the MM/GBSA energy of the minimized complex, and  ELigand is the MM/ GBSA energy of the ligand 
after removing it from the complex and allowing it to relax.  EReceptor is the MM-GBSA energy of relaxed protein 
after separating it from the ligand. The MM-GBSA calculation was performed based on the best pose structure 
obtained from IFD complexes.
Molecular dynamic simulation. Molecular simulations of this study were performed using the Desmond 
v5.3 using Maestro interface (from Schrödinger 2018‐4 suite)34. The appropriate pose for MD simulation proce-
dure of the compound was achieved by IFD method.
In order to build the system for MD simulation, the protein–ligand complexes were solvated with SPC explicit 
water molecules and placed in the center of an orthorhombic box of appropriate size in the periodic boundary 
condition. Sufficient counter‐ions and a 0.15 M solution of NaCl were also utilized to neutralize the system 
and to simulate the real cellular ionic concentrations, respectively. The MD protocol involved minimization, 
pre-production, and finally production MD simulation steps. In the minimization procedure, the entire system 
was allowed to relax for 2500 steps by the steepest descent approach. Then the temperature of the system was 
raised from 0 to 300 K with a small force constant on the enzyme in order to restrict any drastic changes. MD 
simulations were performed via NPT (constant number of atoms, constant pressure i.e. 1.01325 bar and constant 
temperature i.e. 300 K) ensemble. The Nose‐Hoover chain method was used as the default thermostat with 1.0 ps 
interval and Martyna‐Tobias‐Klein as the default barostat with 2.0 ps interval by applying isotropic coupling style. 
Long‐range electrostatic forces were calculated based on particle‐mesh‐based ewald approach with the he cut‐off 
radius for columbic forces set to 9.0 Å. Finally, the system subjected to produce MD simulations for 20 ns for 
each protein–ligand complex. During the simulation every 1000 ps of the actual frame was stored. The dynamic 
behavior and structural changes of the systems were analyzed by the calculation of the root mean square deviation 
(RMSD) and RMSF. Subsequently, the representative frames of the simulation extracted based on the clustering 
method from the equilibrated trajectory system for investigating of ligand–protein complex interaction.
In silico pharmacokinetic properties of synthesized compounds. QikProp module of  Schrodinger35, 
 swissADME36, and  pkCSM37 were used to calculate the important physico-chemical properties of the synthe-
sized compounds like drug-likeness, partition coefficient, solubility, cell permeation.
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